ReAlta’s Pegtarazimod Demonstrates Potential in Reducing Brain Inflammation in Newborns with HIE
A preclinical study reveals pegtarazimod's ability to significantly reduce brain inflammation in newborns with hypoxic ischemic encephalopathy (HIE), offering hope for a new treatment approach.
ReAlta Life Sciences has published findings in the American Journal of Perinatology showcasing pegtarazimod's effectiveness in reducing brain inflammation in a preclinical model of hypoxic ischemic encephalopathy (HIE). The study highlights the peptide's ability to decrease microglial recruitment and oxidative damage, key factors in neuroinflammation associated with HIE and neurodegenerative diseases.
The research builds on Phase 2 STAR trial data, indicating elevated myeloperoxidase (MPO) levels in HIE newborns, with pegtarazimod treatment showing a fourfold reduction in microglial recruitment and significant decreases in MPO staining. This suggests a promising avenue for addressing the unmet medical needs in HIE treatment, currently limited to therapeutic hypothermia.
Dr. Kenji M. Cunnion, ReAlta's Chief Medical Officer, emphasized the importance of these findings in validating pegtarazimod's mechanism of action and its potential to interrupt the inflammatory cascade in neurological diseases. The STAR trial, evaluating pegtarazimod in newborns with HIE, is ongoing, with interim clinical data expected in the latter half of 2025.
Dr. Zachary Vesoulis, a co-author of the study, pointed out the significance of pegtarazimod's anti-inflammatory effects, which could lead to improved outcomes for HIE patients. Pegtarazimod targets both humoral and cellular inflammation, offering a novel approach to treating the inflammatory cascade responsible for brain damage in HIE.